Report Highlights

U.S. Role in the Global Insulin Delivery Device Supply Chain

The United States sits at the centre of insulin delivery device value chains as both a major demand market and design hub. Domestic pen and vial output is anchored by Eli Lilly's Indianapolis complex and Novo Nordisk's Clayton, North Carolina site, while active pharmaceutical ingredient still arrives from Novo's Kalundborg plant in Denmark. Automated insulin delivery platforms from Insulet, Tandem Diabetes Care and Beta Bionics are designed and marketed in the United States, but pump electronics and disposable sub-assemblies are largely contract-manufactured in Mexico, Costa Rica and Asia.

Import dependency is concentrated in disposables rather than hardware. Pen needles, syringes and infusion sets arrive mainly through the Ports of Los Angeles and New York–New Jersey from Asian and European suppliers, while exports remain comparatively small and concentrated in pump platforms shipped to Canada and the United Kingdom. The strategic vulnerability is that the most price-sensitive consumables depend on a few Asian sources, leaving the domestic market exposed to freight and tariff shocks.

Growth Drivers for U.S. Insulin Device Trade and Production

Production capacity is expanding on the back of roughly 38 million Americans living with diabetes, according to CDC estimates, and FDA clearances of automated insulin delivery systems for type 2 patients. Eli Lilly and Novo Nordisk have announced multibillion-dollar expansions, including Novo's USD 4.1 billion Clayton project, which adds fill-finish and device assembly capacity onshore. Each new line increases domestic output of pens and vials that previously crossed the Atlantic for finishing.

Import substitution is the second driver. Tariff pressure from 2025 reciprocal duties and the pending Section 232 review of medical consumables pushes manufacturers to move pen needle and pump sub-assembly lines out of China and into Mexico and Puerto Rico, where USMCA and U.S. territorial treatment preserve duty-free access. Medicare coverage of insulin pumps under the durable medical equipment benefit then converts that nearshored capacity into guaranteed domestic volume.

Supply Chain Risks and Trade Barriers

Raw material and component dependency is the most acute risk. Insulin active ingredient depends on fermentation and purification capacity concentrated in Denmark and Indiana, while pump batteries, microprocessors and polymer tubing draw on single-source suppliers in East Asia. A disruption at one European or Asian node would cascade into shortages across both pens and pumps within a single quarter.

Tariff and logistics exposure compounds the risk. Reciprocal duties and Section 301 tariffs on China-origin goods raise landed costs on disposables, while port congestion during 2021 and 2022 showed how quickly refrigerated insulin shipments slip. Euro-denominated supply contracts add currency risk against the dollar, and FDA registration delays can strand new pump models at the border.

Trade and Investment Opportunities in the United States

The highest-value export opportunity lies in automated insulin delivery platforms sold to Canada, the United Kingdom and Japan, where reimbursement systems increasingly mirror U.S. closed-loop adoption. Inbound FDI is most attractive in pen needle and syringe lines, which remain under-produced domestically, and in Puerto Rico, where medical device manufacturers benefit from tax incentives and direct access to U.S. customs territory.

Import substitution targets are concentrated in disposables, where imports dominate and Section 232 duties could raise costs. Foreign-trade zone designations in Texas, Florida and Puerto Rico let contract manufacturers defer duties on imported components. Laredo, Texas is a viable logistics hub for USMCA-compliant pump sub-assemblies moving north, and Miami is a practical re-export gateway for Latin American distribution.

Market at a Glance

Leading Market Participants

• Insulet Corporation
• Tandem Diabetes Care
• Medtronic MiniMed
• Eli Lilly and Company
• Novo Nordisk
• Sanofi
• Becton, Dickinson and Company
• Embecta Corp
• Ypsomed
• Beta Bionics

Regulatory and Trade Policy Environment

The trade framework for insulin devices is shaped by USMCA, which grants duty-free treatment to qualifying medical devices moving between the United States, Mexico and Canada. Section 301 duties apply to many China-origin syringes and disposables, while most-favored-nation tariff schedules govern imports from Europe and Japan. The 2025 reciprocal tariffs layered additional duties on several supplier countries, and the pending Section 232 review of medical consumables could extend that pressure further.

FDA clearance runs through 510(k) for most pens and pumps, with premarket approval reserved for higher-risk automated systems. Medicare Part B covers insulin pumps and supplies under the durable medical equipment benefit, and CMS has proposed bringing pumps into competitive bidding, which would reshape reimbursement for domestic suppliers. The Inflation Reduction Act's USD 35 monthly insulin cap in Medicare Part D shifts pricing pressure toward devices and consumables.

U.S. Insulin Device Supply Chain Outlook to 2032

Through 2032, the U.S. position shifts from net importer of finished devices toward a higher share of domestic fill-finish and device assembly. Announced Eli Lilly and Novo Nordisk plants will add domestic pen and vial capacity, reducing reliance on European finishing, while nearshored Mexican assembly absorbs pump sub-assembly volume previously shipped from Asia.

Technology will alter comparative advantage. Tubeless patch pumps and smart-pen dose tracking shift value toward software and sensor integration, which favours U.S. design houses over commodity assemblers. Longer-acting insulin formulations reduce daily injection frequency, so suppliers that move into connected platforms will hold their share through 2032.